Moderna, Inc. (NASDAQ:MRNA) is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at ...

Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.

Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research. Moderna’s vaccine is designed to target H5 and H7 ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, we found that the claim is false. According to an Instagram post ...

The claim that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic is false. His remarks at Davos 2023 ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.